✍ Scribed by Michela Bettati; Paolo Cavanni; Romano Di Fabio; Beatrice Oliosi; Ornella Perini; Gunther Scheid; Giovanna Tedesco; Laura Zonzini; Fabrizio Micheli
No coin nor oath required. For personal study only.
Drugs able to interfere with either the uptake or the metabolism of endogenous monoamines have been used for many years to treat depression. The first drugs of this type, such as the monoamine oxidase (MAO) inhibitors and the tricyclic antidepressants, achieved wide diffusion in the market, but are unfortunately associated with side effects that may influence patient compliance. [1] Over the last few years, compounds acting through the selective blockade of neurotransmitter re-uptake have demonstrated their efficacy as successful antidepressant agents. This blockade can take place in either serotoninergic neurons (SSRI; e.g., paroxetine) or noradrenergic neurons (SNRI; e.g., reboxetine). Moreover, drugs known as "dual uptake" inhibitors, which act on both serotoninergic and noradrenergic transporters (e.g., venlafaxine) or on both noradrenergic and dopaminergic transporters (e.g., bupropion), have also demonstrated good efficacy. [1]
📜 SIMILAR VOLUMES
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.